Skip to content

The Medicare GLP-1 Bridge program, criterion by criterion

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

The Medicare GLP-1 Bridge is a CMS demonstration running July 1, 2026 through December 31, 2027. Part D enrollees aged 18 or older who are prescribed Wegovy, Foundayo or the Zepbound KwikPen for weight management and meet the BMI criteria pay $50 per one-month supply. People with type 2 diabetes, moderate to severe obstructive sleep apnea or MASH aren't eligible.

Source: Medicare GLP-1 Bridge

Key takeaways

  • You need an eligible Part D plan, a weight-management prescription, and a qualifying BMI from when you started GLP-1 therapy.
  • Eligible enrollees pay $50 per one-month supply of Wegovy, Foundayo or the Zepbound KwikPen.
  • Type 2 diabetes, moderate to severe obstructive sleep apnea or noncirrhotic MASH with moderate to advanced liver scarring rules you out.
  • If your Part D plan paid for any GLP-1 in 2026, you're not eligible for the Bridge in 2026.
  • There's no patient application and no appeals process. Your prescriber can resubmit with corrected or additional information.

Medicare GLP-1 Bridge: the rules in CMS's words

BMI criteria at the start of GLP-1 therapy
BMIPlus at least one of
35 or higherNothing else needed
30 or higherheart failure with preserved ejection fraction; uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg, despite concurrent treatment with two antihypertensive medications); chronic kidney disease stage 3a or above
27 or higherpre-diabetes (as defined by American Diabetes Association guidelines); previous myocardial infarction; previous stroke; symptomatic peripheral artery disease
  • The Bridge covers Foundayo (tablet), Wegovy (injection or tablet) and Zepbound in the KwikPen only. Single-dose Zepbound vials and single-dose Zepbound pens are not covered, and pen needles for the KwikPen are not covered. CMS says the product list may be updated.

    cms.gov

  • The Bridge is a short-term CMS demonstration that runs from July 1, 2026 through December 31, 2027. It is available nationwide, in all states and territories.

    cms.gov

  • You pay a $50 copay for a one-month supply (28 or 30 days, depending on the drug). Because the Bridge runs outside Part D, the $50 does not count toward your Part D deductible or out-of-pocket (TrOOP) costs, Extra Help (the low-income subsidy) does not lower it, it cannot be spread out with the Medicare Prescription Payment Plan, and coupons or discount programs cannot be applied to it.

    cms.gov

  • Each fill is a single monthly supply (28 or 30 days). 60-day and 90-day fills and partial fills are not available. A vacation override exists at the pharmacy, but there is no override for lost or stolen medication.

    cms.gov

  • Your prescriber, not you, submits the prior authorization (electronically or by fax) after the pharmacy has sent a claim to the Bridge and requested it. The decision is sent to the prescriber and mailed to you within 72 hours of submission. An approval is valid through December 31, 2027 and covers refills and dose changes; a new one is needed only if you switch to a different covered GLP-1. There is no appeals process, but the prescriber can resubmit with corrected or additional information.

    cms.gov

  • Your prescriber sends the prescription to a pharmacy, which bills the Bridge's central processor instead of your Part D plan. Pharmacies do not need to opt in to take part. The pharmacy may ask for your Medicare Number or the last 4 digits of your Social Security Number, and it does not need a denial from your Part D plan first.

    cms.gov

  • An approval can stop working before the program ends. If you later fill a GLP-1 through your Part D plan, or move to a plan type that is not eligible, the pharmacy will get a rejection when you try to refill through the Bridge.

    cms.gov

  • CMS does not say what coverage will exist after December 31, 2027. The only statement on the pages read is that the Bridge was extended through that date ahead of a potential, not confirmed, implementation of the BALANCE Model in Part D.

    cms.gov

See whether you might qualify with the Bridge eligibility checker.

The Medicare GLP-1 Bridge is the only way Medicare pays for a GLP-1 prescribed for weight management. It’s temporary, it sits outside Part D, Medicare’s normal drug benefit, and small details in its rules decide whether a prescription goes through. This page takes those rules one at a time. For the wider picture of what Medicare does and doesn’t cover, start with the Medicare and GLP-1 guide. To test your own situation, use the Bridge eligibility checker, which asks these same questions in order.

What the Bridge is

It’s a short-term demonstration, or test program, run by CMS, the federal agency behind Medicare. It gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs between July 1, 2026 and December 31, 2027. It’s available nationwide, in all states and territories.

It operates outside the Part D benefit’s coverage and payment flow. That one design choice explains most of its unusual features: your plan doesn’t have to opt in, your plan carries no risk for the drug, the deductible doesn’t apply, and nothing you pay counts toward your Part D totals. CMS uses a single central processor for prior authorization, claims and pharmacy payment: Humana, which already administers the LI NET program. The Bridge is the primary payer and doesn’t coordinate benefits with other payers.

Requirements you must meet

1. Part D enrollment in an eligible plan type

You must be enrolled in a standalone prescription drug plan or a Medicare Advantage coordinated care plan that offers drug coverage (HMO, HMOPOS, and Local and Regional PPO plans). People in Special Needs Plans, employer or union group waiver plans and the LI NET program are eligible.

Some plan types are out. If your only Medicare drug coverage is through a private fee-for-service plan, a section 1876 cost contract plan, a section 1833 health care prepayment plan, a PACE organization, a fallback plan or a religious fraternal benefit plan, you’re not eligible unless you’re also enrolled in a standalone drug plan. If you’re not sure what type of plan you have, Medicare says to call 1-800-MEDICARE (1-800-633-4227).

2. Age 18 or older

The Bridge is only available if you’re at least 18.

3. Prescribed for weight management

The drug must be prescribed to reduce excess body weight and maintain weight reduction. The Bridge gives GLP-1s at its copay only for a weight management indication. A GLP-1 prescribed for a use Part D covers should come through your Part D plan.

4. Used with lifestyle modification

Your prescriber must attest that you’re using the drug together with current and ongoing lifestyle modification, including structured nutrition and physical activity. The sources differ slightly here: the prior authorization form adds “unless physical activity is not clinically appropriate,” which the CMS question-and-answer wording doesn’t include.

5. BMI at the time you started GLP-1 therapy

You must meet one of three tiers:

  • BMI 35 or higher. No other condition required.
  • BMI 30 or higher with at least one of: heart failure with preserved ejection fraction; uncontrolled hypertension, defined as systolic blood pressure above 140 mm Hg or diastolic above 90 mm Hg despite concurrent treatment with two antihypertensive medications; or chronic kidney disease stage 3a or above.
  • BMI 27 or higher with at least one of: pre-diabetes as defined by American Diabetes Association guidelines; previous myocardial infarction (heart attack); previous stroke; or symptomatic peripheral artery disease.

The timing matters. CMS says beneficiaries must meet the clinical criteria at the time of GLP-1 therapy initiation, and that this includes people who started therapy before enrolling in Part D or before the Bridge launched. So the BMI that counts is your starting BMI, even if it’s lower now. A BMI below 27 doesn’t qualify.

Exclusions that rule you out

Your Part D plan has paid for a GLP-1 in 2026

If your Part D plan has paid for any GLP-1 for you in calendar year 2026, for any reason, you’re not eligible for the Bridge in 2026. That holds even if the coverage was supplemental coverage of weight management by your plan. CMS checks its own data, and the drugs in that review are Zepbound, Mounjaro, Foundayo, Rybelsus, Ozempic, Wegovy, Saxenda, Victoza and Trulicity. If you’re ineligible for this reason, your pharmacy receives a notification.

CMS sets the lookback period that applies during 2027.

Type 2 diabetes, sleep apnea or MASH

A diagnosis of type 2 diabetes, moderate to severe obstructive sleep apnea, or noncirrhotic MASH with moderate to advanced liver scarring makes you ineligible, whether or not your current Part D plan covers a GLP-1 for that condition. CMS’s reasoning is that these indications are eligible for Part D coverage, so the request goes to the plan.

The pages word the liver condition differently. The prior authorization form uses the full clinical phrase, while Medicare.gov simply says “fatty liver disease.” The form’s wording is what your prescriber attests to.

Prescribed to reduce cardiovascular risk

This one is subtler. Having established cardiovascular disease doesn’t exclude you, and a previous heart attack or stroke is a qualifying condition at BMI 27 or higher. But if the drug is being prescribed in order to reduce the risk of major adverse cardiovascular events, even when it’s also prescribed for weight, CMS says that prescription should go to the Part D plan.

What is covered, and what you pay

Covered products. All formulations of Foundayo, all formulations of Wegovy, and the KwikPen formulation of Zepbound. The single-dose vial and single-dose pen formulations of Zepbound aren’t available. CMS says the list of products may change during the program. Our pages on Wegovy and Zepbound cover the drug-specific details.

Pen needles. Not covered by the Bridge, and not to be billed to your Part D plan either. You buy them separately.

Copay. $50 for a one-month supply. Because the Bridge runs outside Part D:

  • the Part D deductible doesn’t apply
  • no part of the copay counts toward your true out-of-pocket costs
  • there’s no low-income subsidy, so Extra Help doesn’t lower it
  • you can’t spread it out with the Medicare Prescription Payment Plan
  • coupons and discount programs may not be applied, regardless of funding source

Behind the copay, manufacturers provide the drugs at a net price of $245 per monthly supply, none of which counts toward your Part D gross drug costs. The Part D costs page explains how this differs from a drug your plan covers.

Quantity. One monthly supply (28 or 30 days) per fill. No 60-day or 90-day fills and no partial fills. A vacation override exists at the pharmacy, but there’s no override for lost or stolen medication.

How the prior authorization works

A prior authorization is the approval that has to be in place before a fill goes through. Here’s how it runs:

  1. Your prescriber sends the prescription to a pharmacy. Pharmacies don’t need to opt in.
  2. The pharmacy sends the claim to the Bridge’s central processor, not to your Part D plan. It doesn’t need a denial from your plan first. It may ask for your Medicare Number or the last 4 digits of your Social Security Number.
  3. The pharmacy requests the prior authorization, and your prescriber submits it electronically or by fax. CMS tells prescribers to wait for the pharmacy’s request. Only prescribing clinicians can submit the form.
  4. The approval or denial is sent to your prescriber and mailed to you within 72 hours of submission.

An approval is valid through December 31, 2027. Refills and dose changes don’t need a new one. Switching from one covered GLP-1 to a different one does.

There’s no appeals process. Your prescriber can resubmit with corrected or additional information.

How you can lose eligibility after approval

An approval isn’t a guarantee through the end of the program. Two things stop it working:

  • A later Part D fill. If you fill through the Bridge and then fill a GLP-1 through your Part D plan, you’re no longer eligible, and the pharmacy receives a rejection on your next Bridge refill.
  • A plan change. If you move to an ineligible plan type, such as a private fee-for-service plan, a cost contract plan or a PACE organization, the pharmacy also receives a rejection.

Keep this in mind during Medicare open enrollment. A change of plan type can end your Bridge access even though your health hasn’t changed.

What happens after December 31, 2027

CMS doesn’t say. The Bridge was extended through that date to give access and to let CMS collect data on GLP-1 use to share with Part D plan sponsors ahead of a potential implementation of the BALANCE Model in Part D. That implementation isn’t confirmed. The BALANCE Model page explains what that model is and where it stands.

Frequently asked questions

What BMI do you need for the Medicare GLP-1 Bridge?

A BMI of 35 or higher qualifies on its own. A BMI of 30 or higher qualifies with heart failure with preserved ejection fraction, uncontrolled hypertension or chronic kidney disease stage 3a or above. A BMI of 27 or higher qualifies with pre-diabetes, a previous heart attack, a previous stroke or symptomatic peripheral artery disease. The BMI that counts is the one you had when you started GLP-1 therapy.

I already take a GLP-1. Can I move to the Bridge?

It depends on who has been paying. If your Part D plan paid for a GLP-1 in 2026 for any reason, you're not eligible and should keep getting it through the plan. A GLP-1 paid for outside Part D, with cash or other insurance, isn't what that exclusion describes. CMS says the clinical criteria are judged at the time you first started therapy.

Do I apply for the Medicare GLP-1 Bridge myself?

No. There's no patient application. Your prescriber sends the prescription to a pharmacy. The pharmacy sends a claim to the Bridge and requests the prior authorization, and your prescriber submits it electronically or by fax. The decision is sent to your prescriber and mailed to you within 72 hours of submission.

Can I get a 90-day supply through the Bridge?

No. Each fill is a single monthly supply of 28 or 30 days, depending on the drug. Sixty-day and ninety-day fills aren't available, and neither are partial fills of less than a month. The pharmacy has a vacation override, but CMS says there will not be any overrides for lost or stolen medication.

What if my Bridge prior authorization is denied?

There's no appeals process under the Medicare GLP-1 Bridge. Your prescriber can resubmit the request with corrected or additional information. If the denial is because you have a condition Part D covers GLP-1s for, such as type 2 diabetes, the request belongs with your Part D plan, which has its own formulary exception process.

What happens when the Bridge ends?

CMS hasn't said what coverage will exist after December 31, 2027. Its only statement is that the Bridge was extended through that date ahead of a potential implementation of the BALANCE Model in Part D. Prior authorization approvals are valid through December 31, 2027 and not beyond.

Sources (7)

  1. 1.
    CMS: Information for Part D Plans
    “Under the Medicare GLP-1 Bridge, participating manufacturers will provide eligible GLP-1 drugs at a net price of $245 per monthly supply. Coverage of eligible GLP-1 drugs furnished under the Medicare GLP-1 Bridge is provided outside of the Part D benefit payment flow and coverage. As such, no part of the $245 net price for eligible GLP-1 drugs prescribed for uses covered under the Medicare GLP-1 Bridge would count toward an eligible beneficiary’s gross covered prescription drug costs (GCPDC), and no part of the $50 copay would count toward the beneficiary’s true out-of-pocket costs (TrOOP) under their Part D plan.”
  2. 2.
    CMS: Information for Part D Plans
    “CMS will be utilizing Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, as the central processor for the Medicare GLP-1 Bridge. [...] The Medicare GLP-1 Bridge will be the primary payer for products covered under the Medicare GLP-1 Bridge and will not coordinate benefits with other payers.”
  3. 3.
    CMS: Medicare GLP-1 Bridge
    “The Medicare GLP-1 Bridge will operate outside of the Medicare Part D benefit’s coverage and payment flow. As a result, Part D sponsors will not carry risk for eligible GLP-1 drugs furnished under the Medicare GLP-1 Bridge, and Part D sponsors do not have to opt in to the Medicare GLP-1 Bridge for eligible beneficiaries to access these drugs beginning July 1, 2026.”
  4. 4.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  5. 5.
    CMS: Information for Part D Plans
    “Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
  6. 6.
    CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
    “Will the Medicare GLP-1 Bridge continue into 2027? Yes. The Medicare GLP-1 Bridge has been extended through December 31, 2027. [...] What is the impact of the BALANCE Model not launching in Medicare in 2027 on the Medicare GLP-1 Bridge? The Medicare GLP-1 Bridge will be extended through December 31, 2027, providing eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs and allowing CMS to collect additional data on GLP-1 utilization to share with Part D plan sponsors ahead of potential implementation of BALANCE in Part D.”
  7. 7.